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Abstract
Iron–sulfur clusters are evolutionarily conserved biological structures which play an important role as cofactor for multiple 
enzymes in eukaryotic cells. The biosynthesis pathways of the iron–sulfur clusters are located in the mitochondria and in 
the cytosol. The mitochondrial iron–sulfur cluster biosynthesis pathway (ISC) can be divided into at least twenty enzymatic 
steps. Since the description of frataxin deficiency as the cause of Friedreich’s ataxia, multiple other deficiencies in ISC bio-
synthesis pathway have been reported. In this paper, an overview is given of the clinical, biochemical and genetic aspects 
reported in humans affected by a defect in iron–sulfur cluster biosynthesis.
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Introduction
In eukaryotes, the Fe/S-cluster biosynthesis machinery is 
classically divided into the mitochondrial iron–sulfur clus-
ter assembly (ISC) and export machinery, and cytosolic 
iron–sulfur protein assembly (CIA) system. Nowadays, 9 
CIA proteins and 20 ISC proteins are known to assist the 
major steps in biogenesis. All steps in these machineries are 
evolutionarily conserved from yeast to man. Once incor-
porated into their target protein, Fe/S-cluster function as 
catalysts or take part in electron transfer. They also serve 
as sulfur donors in lipoate and biotin cofactor biosynthesis 
[1]. Fe/S-cluster-bearing proteins are located in the mito-
chondria and in the cell nucleus, where they play a role in 
gene expression regulation [2]. Moreover, proteins involved 
in DNA replication, DNA repair (Pol α, Pol ε, Pol δ, and 
Pol γ) and those functioning as DNA helicase harbor Fe/S 
clusters [3]. The cytosolic ABC protein ABCE1 required 
for ribosome assembly and protein translation has two 
[4Fe/4S] clusters [4]. Apart from being synthesized and 
incorporated as cofactor into apoproteins, iron–sulfur clus-
ters also serve as redox center, as they are incorporated in 
the complexes I, II, and III of the oxidative phosphorylation 
system (OXPHOS), embedded in the inner mitochondrial 
membrane.
Considering the pleiotropic subcellular localization and 
the essential role of the Fe–S-cluster-bearing enzymes in 
cell viability, it is easy to understand that faulty synthesis 
and lack of insertion of these inorganic elements can have 
detrimental effects on human health. An overview will be 
given of the genetic and clinical aspects of the molecular 
defects located in the biosynthesis pathway of iron–sulfur 
clusters in the mitochondria. Until now, diseases resulting 
from pathogenic mutations in proteins involved in CIA have 
not been reported.
Mitochondrial iron–sulfur biosynthesis (ISC)
ISC can be divided into three major steps. The first part 
encompasses formation of a [2Fe–2S] Fe/S cluster on a 
scaffold protein. Subsequently, the cluster released from 
the scaffold protein by dedicated chaperones is maintained 
in a gluthatione (GSH)-dependent fashion. The synthe-
sized product is further processed intramitochondrially or 
exported into the cytosol to be processed by CIA. The exact 
nature of the exported structure is unknown, but it might be 
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a glutathione-stabilized [2Fe–2S] ([2Fe–2S](GS)42−) [5]. The 
export of this structure is mediated by ABCB7 in coopera-
tion with ALR, an FAD-dependent sulfhydryl oxidase. The 
implication of ALR is, however, still a matter of debate, as 
a study in yeast could not show impaired cytosolic iron–sul-
fur cluster assembly [6]. The mitochondrial machinery can 
synthesize [2Fe–2S] or [4Fe–4S] clusters and incorporate 
these into the appropriate apoproteins (Fig. 1). For a detailed 
description of the iron–sulfur cluster pathway and the spe-
cific role of each enzyme within this pathway, we refer to 
other papers within this issue.
Faulty ISC synthesis can lead to mitochondrial failure, 
preferentially affecting high energy consuming organs, i.e., 
central nervous system, skeletal muscle, heart muscle, and 
liver. A deficiency in ISC synthesis can thus mimic clinical 
phenotypes of oxidative phosphorylation defects (Table 1). 
Considering the intricate relationship between ISC biosyn-
thesis and cellular iron homeostasis, ISC deficiencies can 
lead to iron accumulation. 
De novo synthesis of [2Fe–2S] clusters
One of the mitochondrial matrix proteins dedicated to Fe–S-
cluster synthesis is ISCU [7]. The ferrous iron required for 
Fe/S synthesis is imported into the mitochondria through the 
mitochondrial solute carriers mitoferrin 1 (SLC25A37) and 
2 (SLC25A28). In contrast to mitoferrin 1, which is exclu-
sively expressed in developing erythroid cells, mitoferrin 
2 is widely expressed [8]. How iron gets into the scaffold 
protein is not totally elucidated yet, but frataxin (FXN) plays 
an important role in this process at least in humans. Interac-
tion of frataxin with ISCU is important for ISC biosynthesis 
and seems to be iron dependent [9]. The sulfur component 
is delivered through desulfuration of cysteine into alanine 
by cysteine desulfurase (NFS1), acting in a dimer conforma-
tion, in association with the cofactor pyridoxal 5’ phosphate. 
In addition, NFS1 requires association with a heterodimer 
composed of ISD11 (encoded by LYRM4) and acyl carrier 
protein (ACP) [10] for stabilization [11].
ISCU
As ISCU functions as a scaffold protein at the start of Fe/S-
cluster synthesis, defective ISCU is predicted to impair over-
all cluster synthesis resulting in large downstream effects, 
often with lethal consequences. This was confirmed in mice 
[12]. However, tissue specific splicing and partial enzymatic 
impairment are found in subjects harboring pathogenic vari-
ants in ISCU. ISCU deficiency can cause myopathy with 
exercise intolerance and lactic acidosis, which is called the 
Swedish type myopathy. Subjects may experience cramps 
and show rhabdomyolysis. Interestingly, most of the affected 
subjects carry the common homozygous intronic mutation 
(7044G > C, or IVS5 + 382G-C), and all of them (except 
for one Norwegian) are native from a region in Northern 
Sweden, explaining the denomination of Swedish myopathy 
[13]. In 2009, two siblings were identified with an exonic 
missense mutation (149G > A, Gly50Glu) in a compound 
heterozygous state, which includes the common intronic 
Fig. 1  Schematic representation of the intramitochondrial iron–sulfur cluster biosynthesis pathway (see text for details)
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Table 1  Overview of the reported ISC related diseases showing the causative genes, the clinical, biochemical and morphological features
Gene Clinical features Biochemical and morphological features References
SLC25A37: RARS (myelodysplastic syndrome with isolated anemia 
ineffective erythropoiesis)
Increased expression of mitoferrin 1 16
ISCU: Myopathy with exercise intolerance
Severe myopathy with hypertrophic cardiomyopathy




FXN: Friedreich’s ataxia (progressive ataxia, dysarthria, diabe-
tes mellitus, cardiomyopathy) < 20 years
Aconitase deficiency




Hypotonia, multiple organ failure, epilepsy
Developmental delay, hypotonia
Decreased complex II and III activity (muscle, liver)
Absence of LYRM4
30
LYRM4: (Transient) hypotonia ± epilepsy Decreased complex I, II, and III activity (muscle, liver)
Decreased expression: aconitase, ferrochelatase
31
FDXR: Auditory neuropathy and optic atrophy Decreased complex I, III, (IV, V) (fibroblasts)
Iron accumulation, aconitase deficiency (fibroblasts)
33
FDXL2: Myopathy (cramps, rhabdomyolysis, myoglobinuria) Increased lactate
Decreased complex I, II, and III activity (muscle, liver)
Aconitase deficiency
34
HSPA9: EVEN-PLUS syndrome Ineffective hematopoiesis (zebrafish) [38, 39]
GLRX5: Lower limb spasticity, optic nerve atrophy
Congenital sideroblastic anemia ± diabetes mellitus 
type1 ± cirrhosis ± hypogonadism
Increased lactate (serum) and glycine (CSF)
Normal OXPHOS activity (muscle)
Defective lipoylation (fibroblasts)
Ring sideroblasts; iron accumulation (fibroblasts)
Increased ferritin (serum)
[7, 41–43]
ABCB7: Sideroblastic anemia, ataxia ± cerebellar atrophy
Female carriers: anemia
Mild hypochromic, microcytic anemia
Variable ferritin (serum)
Normal OXPHOS activity (fibroblasts)
[45, 46, 48]
ALR: Developmental delay, hypotonia (± dystonia, choreic 
movements), congenital cataract ± hearing loss
Increased lactate (serum)
Decreased complex I, II, III, and IV activity (muscle,
fibroblast)
[51–53]
ISCA1: Regression, seizures, progressive leukodystrophy Increased lactate 57
ISCA2: Diffuse progressive leukodystrophy Isolated complex I deficiency (fibroblasts)
Decreased complex I, II, and III activity (HeLa)
Decreased aconitase activity (HeLa)
58
IBA57: Microcephaly, hypotonia, encephalopathy, dysmorphism
Regression, leukodystrophy
Spastic paraparesis, peripheral neuropathy ± optic nerve 
atrophy (SPOAN)
Increased lactate and glycine (serum, CSF)
Faulty lipoylation
Decreased complex I, II, and IV activity (muscle, fibro-
blasts)
Decreased aconitase activity (fibroblasts)
Decreased complex I, II, and III activity (HeLa)
[60–64]





Increased glycine (serum and CSF)
Increased lactate (serum)
Faulty lipoylation
Decreased complex II and PDHC activity (muscle)
(variable OXPHOS deficiencies in tissues)
[68, 70–72]
BOLA3: Epileptic encephalopathy, cardiomyopathy
Hypertrophic cardiomyopathy, regression, epilepsy
Spasticity, ataxia, regression, epilepsy
Increased glycine (serum, CSF)
Increased lactate (serum)
Faulty lipoylation
Decreased complex I and II (fibroblasts, muscle)




Developmental delay, ataxia, spasticity,  
white matter alterations
Increased lactate (serum, CSF)
Deficient complex I activity (muscle, fibroblasts
[74, 76]
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mutation. They had a more severe phenotype with early 
onset (around the age of 2 years) of severe muscle weakness 
and muscle wasting, and hypertrophic cardiomyopathy [14]. 
Very recently a dominant mode of inheritance (c.287G > T, 
pGly96Val) was reported in an Italian subject presenting 
with ptosis, hypotonia and exercise intolerance, showing 
worsening over time [15]. Biochemical features were dif-
ferent from previously reported cases, including complex IV 
deficiency in addition to the classically reported complex I, 
II, and III deficiencies [15]. Analysis of transcript expression 
showed that the highest level of mutant transcript was in 
skeletal muscle (80%), while liver and heart had lower levels 
(46 and 30%, respectively), explaining the tissue specific 
phenotype of this disease [12].
SLC25A37 and SLC25A28
Disease-causing mutations have not been detected yet in 
genes encoding these proteins. However, in the subjects with 
refractory anemia and ring sideroblasts (RARS), increased 
expression of mitoferrin 1 (SLC25A37) in bone-marrow 
mononuclear cells was found [16]. RARS is a form of mye-
lodysplastic syndrome leading to isolated anemia, hypochro-
mic erythrocytes, hyperplastic ineffective erythropoiesis and 
mitochondrial ferritin accumulation in erythroid precursor 
cells.
FXN
Being involved early in the ISC synthesis pathway, a 
decrease of frataxin protein has an impact on the over-
all Fe/S-cluster synthesis. Indeed, frataxin null mutations 
were shown to be lethal in mice [17]. Defective frataxin 
protein is seen in Friedreich’s ataxia. The latter is caused 
by the presence of a triplet repeat expansion (GAA) in 
the first intron of the FXN gene in the homozygous or in a 
compound heterozygous state with a missense or nonsense 
mutation [18, 19]. The disease is characterized by progres-
sive ataxia, the absence of lower limb tendon reflexes, dys-
arthria, limb weakness leading to loss of ambulation after 
several years, decreased vibration sense, scoliosis, diabetes 
mellitus and cardiomyopathy. The neurological symptoms 
reflect specific vulnerability of dorsal root ganglia, sensory 
peripheral nerves, corticospinal tract and dentate nucleus 
[20]. The age of onset is before 20 years. The length of 
the triplet expansion correlates directly with left ventricu-
lar wall thickness [21] and inversely correlates with age 
of onset and faster exacerbation of symptoms [22]. The 
affected subjects become ultimately wheelchair bound 
and cardiomyopathy is often the cause of fatal outcome. 
Cardiomyopathy seldom causes death before neurological 
symptoms are fully developed [23]. In accordance with the 
early involvement of the frataxin protein in ISC biosynthe-
sis pathway, deficiencies of aconitase and of the OXPHOS 
complexes I, II, and III have been reported in subject’s car-
diomyocytes [24]. Mitochondrial iron accumulation was 
another striking finding. In cultured skin fibroblasts from 
of Friedreich’s ataxia patients, the activities of complexes 
I and II were decreased [25].
Importantly, Friedreich’s ataxia is the first iron–sulfur 
cluster deficiency for which therapeutic options are being 
developed. Currently, 51 clinical trials are going on or 
have recently been completed. These are studying differ-
ent therapeutic approaches aiming (a) to reduce intrami-
tochondrial oxidative stress (idebenone, coenzymeQ, vita-
min E, iron chelators), (b) to enhance frataxin endogenous 
expression (erythropoietin, pioglitazone), or (c) to increase 
FRDA gene expression (HDAC inhibitors, interferon γ). 
For further detailed information on this topic, we refer to 
recently published papers [26, 27]. Some of the proposed 
strategies, alone or combined, showed improvement on 
disease rating scales, but are not disease-modifying or cur-
ing. However, more promising results are emerging from 
gene therapy. In a conditional mouse model with complete 
Fxn deletion in cardiac muscle, intravenous administration 
of adeno-associated virus (AAV) rh10 vector expressing 
human FXN intravenously prevented occurrence of car-
diomyopathy or completely restored heart function [28]. 
Increased frataxin expression in patient derived lymph-
oblast was observed after excising the GAA expansion 
repeat in one allele using zinc finger nuclease [29].
NFS1
Not much is known about the clinical characteristics of 
an NFS1 protein defect in humans as only one report was 
published until now describing three subjects from consan-
guineous descent all sharing the same homozygous missense 
mutation, c.215G > A, p.Arg72Gln [30]. This conserved 
residue was recognized to be an important residue for the 
hydrogen bond formation between NFS1 and ISD11 [10, 
11]. The first subject presented at 7 months of age with leth-
argy, myocardial failure, and generalized seizures during an 
infectious episode ultimately leading to fatal outcome 3 days 
later. The second subject presented with hypotonia and feed-
ing problems, and developed multiple organ failure, as well 
as focal seizures due to cerebral infarction. Heart failure was 
the cause of death at the age of 7 months. The third subject 
who was started on vitamin supplementation since the age 
of 6 months was still alive at 11 years and suffered from mild 
developmental delay and truncal and limb hypotonia [30]. 
Biochemical features included increased lactate in body 
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fluids and decreased complex II and III activity in skeletal 
muscle and liver (complex I not tested individually) [30].
ISD11
LYRM4 encodes iron–sulfur protein biogenesis desulfurase 
interacting protein 11kDa (ISD11). Until now, only two sub-
jects were reported with homozygous pathogenic missense 
variant in LYRM4. Although both harbored the same geno-
type, their phenotypes were different. One subject was alive 
at 20 years of age without symptoms, while the other died 
at the age of 2 months. The first presented with respiratory 
distress and hypotonia during the neonatal period. There-
after, he improved gradually and was lost to follow-up, but 
reevaluation at age 20 years showed no remarkable clini-
cal anomalies. The latter suffered from neonatal respiratory 
distress and had hepatomegaly. She developed seizures. Her 
clinical condition deteriorated and ultimately became fatal. 
Both subjects showed no anomalies on cerebral imaging 
[31]. The different outcomes in both individuals could pos-
sibly be explained by the availability of sulfur sources during 
the first weeks of life. Indeed, availability of cysteine, the 
major sulfur source, is restricted in the neonatal period due 
to reduced activity of hepatic cystathionase [32]. Affected 
individuals showed increased lactate in body fluids due to 
impaired complex functioning of the OXPHOS complexes I, 
II, and III in skeletal muscle and liver. In both tissues, cyto-
solic and mitochondrial aconitase and also ferrochelatase 
showed decreased expression. Incorporation of the mutation 
in S. cerevisiae resulted in growth restriction. In E. coli, the 
variant had no impact on the oligomerization of ISD11 with 
its partner protein NFS1. The enzymatic desulfurase activity 
was severely impaired in the same model [31].
FDXR
FDXR deficiency has only recently been reported. In one 
paper, eight individuals from four different families were 
described. The core clinical features were restricted to sen-
sorineural hearing loss (auditory neuropathy) and optic atro-
phy. Age of onset for hearing impairment ranged from five to 
20 years and from 2 to 36 years for visual impairment. Brain 
imaging revealed no abnormalities. All individuals had mis-
sense mutations, except for one who had a nonsense muta-
tion in compound heterozygous status. Biochemical analysis 
in affected subjects was performed in cultured skin fibro-
blasts showing impaired complexes I, III, IV, and V in one 
subject and impairment of complexes I and III in the other. 
The absence of complex II involvement was remarkable, 
certainly considering the decreased expression of SDHB. 
Finally, iron overload, in combination with decreased IRP1 
content, was noticed [33].
FDX2
Only one subject with a defect in FDX2 (encoded by the 
FDXL) was reported, so far. A homozygous missense 
mutation in the start codon resulted in a severe decrease 
of expression of FDXL. The subject suffered from myopa-
thy characterized by episodes of acute cramps, rhabdomy-
olysis, and myoglobinuria after moderate physical activity. 
During follow-up, a slowly progressive muscle weakness 
was noticed. The mental capacities were not altered. Dur-
ing acute episodes, serum lactate was increased. OXPHOS 
activity analysis in skeletal muscle showed typical features 
of Fe/S-cluster deficiency with decreased activities of com-
plexes I, II, and III, and a decreased activity of the Fe/S-
cluster matrix enzyme aconitase [34].
Interestingly, the clinical presentation of FDX2 deficiency 
mimics the phenotype of individuals with ISCU deficiency. 
Tissue specific splicing cannot be an explanation for the 
skeletal muscle specific phenotype as FDX2 is expressed 
ubiquitously. The authors suggest that FDX2 is not a vital 
component in Fe–S biogenesis and that FDX1 may partly 
take over the function in basal conditions, but not in extreme 
conditions [34].
[2Fe–2S] cluster release
Cluster release starts by binding of the J-type co-chaperone 
HSCB (HSC20, Jac1), and HSPA9 (mortalin, HSPA9B) to 
the ISCU-Fe/S, resulting in loosening of the [2Fe–2S] clus-
ter in an ATP dependent process [36]. In addition, GLRX5, 
possessing a [2Fe–2S] cluster itself, binds to the complex 
in a dimeric conformation and recruits GRPEL1 for final 
cluster release [35, 36]. Synthesized [2Fe–2S] clusters or 
intermediate elements meant for further processing by the 
cytosolic iron–sulfur machinery are exported by the ABCB7 
translocator. The FAD-dependent sulfhydryl oxidase ALR is 
thought to support the export [37]. It is generally accepted 
that proper cytosolic ISC synthesis relies on exported mito-
chondrial intermediates. Subsequently, we can conclude that 
all protein deficiencies occurring before this stage can lead 
eventually to disruption of cytosolic ISC synthesis, and ulti-
mately to mitochondrial iron overload.
HSPA9
This heat shock protein is associated with cluster release. 
It is supposed to have many other functions, including cor-
rect folding of proteins after being imported into the mito-
chondria. Three subjects with a HSPA9 deficiency carried 
a homozygous missense mutation or missense mutation in 
a compound state with a nonsense mutation. Affected sub-
jects presented overlapping symptoms recollected in the 
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acronym EVEN-PLUS syndrome, reflecting epiphyseal, ver-
tebral, ear and nose malformation, plus associated findings 
[38]. Indeed, all subjects presented ‘bifid’ distal femurs and 
epiphyseal dysplasia of the femur head, resulting in short 
stature, bilateral microtia and hypoplastic nasal bones. One 
subject showed vertebral coronal clefts and another lat-
eral vertebral clefts. Other findings comprised arched eye-
brows with mild synophrys and atrial septum defects for all 
reported patients. Two of them had anal atresia and a small 
area of aplasia cutis. One had hypodontia, which is another 
feature of ectodermal tissue involvement. Only one subject 
presented with developmental delay and had abnormal cer-
ebral imaging (dysgenesis of the corpus callosum). This sub-
ject also had vesico-ureteral reflux and kidney nephropathy 
[38]. Biochemical features in affected subjects were not 
provided, except for the reported anemia. Indeed, a HSPA9 
deficient zebrafish, called ‘crimsonless’, showed ineffective 
hematopoiesis and also deleterious effects on early devel-
opment of musculature, fins and internal organs leading to 
death at the 72 hpf stage [39]. An acquired interstitial dele-
tion of the long arm of chromosome 5 [del(5q)] creating 
haploinsufficiency for a large set of genes including HSPA9 
haploinsufficiency is a known cause of myelodysplastic syn-
drome characterized by ineffective hematopoiesis [40].
GLRX5
Although the number of reported patients is still limited, 
two clearly distinct phenotypes, characterized either by 
isolated spasticity of the lower limbs or by isolated side-
roblastic anemia, can be found. An erythroblastoid phe-
notype is expected, considering the abundant expression 
of GLRX5 in erythroid cells (CD71 +) and only minimal 
expression in other tissues [7]. However, in mice apart 
from erythroblasts high expression of GLRX5 was also 
demonstrated in the hippocampus and Purkinje cells of 
the cerebellum [7].
Three individuals with GLRX5 deficiency, caused by 
homozygous in frame deletion or out of frame insertion lead-
ing to premature stop codon in combination with the same 
in frame deletion, were identified in a cohort of patients 
with non-ketotic hyperglycinemia (NKH). In contrast to the 
classical presentation of NKH characterized by neonatal epi-
leptic encephalopathy, these subjects developed symptoms 
much later and showed a milder disease course. One subject 
had only mild learning difficulties and two individuals had 
normal mental development, but one of them suffered from 
progressive deterioration of vision, in accordance with pro-
gressive optic nerve atrophy. Spasticity of the lower limbs 
occurred between the age of 2 and 7 years. These symptoms 
correlated with varying degrees of diffuse and progressive 
white matter alterations seen on brain MRI in two subjects, 
and only mild alteration of the upper spinal cord in another. 
All patients were still alive at the time of publication of the 
paper, i.e., aged between 7 and 11 years [41].
Two adults, both harboring missense mutations, were 
described with congenital sideroblastic anemia and hepato-
splenomegaly, without signs of spasticity. Later, in the dis-
ease course, they developed diabetes mellitus type 1 [42, 
43]. One patient had cirrhosis and hypogonadism [42].
Biochemical analysis in the subjects with the spastic phe-
notype showed increased glycine concentration in serum 
and cerebrospinal fluid (CSF). In accordance, the activity 
of glycine cleavage enzyme in liver tissue was low in all 
subjects. This was probably due to defective lipoylation of 
the H-protein moiety. Defective lipoylation of αKGDH and 
PDHC has already been demonstrated in cultured skin fibro-
blasts. Activity of OXPHOS complexes was not tested in 
all patients, but OXPHOS activities were not defective in 
cultured skin fibroblasts and skeletal muscle. Lactate was 
normal in these subjects [41].
In the probands with sideroblastic anemia, a signifi-
cant amount (> 15%) of ring sideroblasts was detected in 
bone-marrow smears. Apart from erythroid iron accumula-
tion, transferrin saturation and ferritin concentration were 
increased in serum. Further evidence of defective ISC bio-
synthesis was provided by decreased Fe/S incorporated in 
cytosolic aconitase and decreased catalytic activity of this 
enzyme [42, 43]. Activities of the mitochondrial aconitase 
and complex II were normal in lymphoblasts [41]. How-
ever, complex I activity and complex I expression were 
significantly decreased in cultured skin fibroblasts [7]. The 
cultured skin fibroblasts also showed increased iron accumu-
lation, both in mitochondria and cytosol [7]. Interestingly, 
therapy with the iron chelator, deferoxamine, resulted in 
improvement of anemia in both patients [42, 43].
In HeLa cells depleted of GLRX5, a decreased activity of 
mitochondrial aconitase and xanthine oxidase was detected, 
confirming the essential role for cytosolic and mitochondrial 
ISC, both [4Fe–4S] and [2Fe–2S] clusters. These cells also 
showed increased (approximately doubled) total non-heme 
mitochondrial iron content and lower ferritin expression [7].
ABCB7
Deficient export of ISC or ISC intermediates results in iron 
accumulation in mitochondria. As synthesis per se is not 
affected, OXPHOS complexes are not deficient. Comple-
mentation studies in yeast showed the importance of ABCB7 
protein for cytosolic ISC maturation. A defect in ABCB7 
resulted in abolition of the activity of cytosolic aconitase, 
which functions as an iron regulatory protein (IRP), leading 
to increased transferrin receptor synthesis and subsequent 
increase in iron uptake. Anemia is explained by decreased 
ferritin and decreased erythroid 5-aminolevulinate synthase 
(ALAS2) synthesis.
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All reported subjects with either hemizygous or heterozy-
gous missense mutations presented with sideroblastic ane-
mia in combination with ataxia. Although classically a non-
progressive ataxia was reported, some adult patients suffered 
from regression of motor function. Early motor development 
varied from normal to delayed. Age of onset of the central 
nervous symptoms varied from early childhood to late adult-
hood. Ocular symptoms with nystagmus and/or small sac-
cades were reported in three adults [44]. Cerebral imaging is 
normal or shows isolated cerebellar atrophy. Heterozygous 
females may suffer from hypochromic microcytic anemia, 
but do not present with neurological symptoms [45–48]. 
More recently, isolated cerebellar hypoplasia without side-
roblastic anemia was reported in the affected individuals 
in one family. These individuals also harbored a deletion 
on chromosome X, affecting two other genes (ATP7A and 
PGAM4) that might have influenced the phenotype [49].
ALR
The ALR protein is encoded by the GFER gene. It is an 
oxidase essential for the mitochondrial disulfide relay sys-
tem, which is extremely important for protein import into 
the mitochondrial intermembranary space [50]. ALR may 
be involved in export of ISC synthesized intermediates into 
the cytosol [37].
Affected subjects, all harboring missense mutations, have 
variable degrees of developmental delay, hypotonia and con-
genital cataract. In serum, lactate is increased.
In the first report, three subjects of consanguineous ori-
gin were described presenting with congenital cataracts, 
early onset progressive muscular hypotonia, sensorineural 
hearing loss, delay of motor skills and speech development 
[51]. In a second paper, an adult subject was described with 
infantile-onset adrenal insufficiency, cataract and subse-
quently poor feeding, irritability and hepatomegaly. Cerebral 
imaging revealed mildly increased signals bilaterally in the 
globus pallidus, which was resolved later on. By the age 
of 18 months the clinical situation stabilized and the child 
had only a slightly delayed development. At an early adult 
age, truncal hypotonia and muscle wasting were noticed, 
leading to respiratory insufficiency [52]. Very recently, two 
families, each with two affected siblings, were reported. Two 
siblings presented with regression at the age of 9 months 
associated with hypotonia evolving to severe developmental 
delay, dystonia, choreic movements and absent or minimal 
language development. Cerebral imaging showed moderate 
brain atrophy in one sibling. The other two subjects also 
presented with developmental delay associated with hypo-
tonia and mild dystonic features. All reported subjects had 
congenital cataracts, and none had hearing loss [53].
When tested, serum lactate was found to be increased 
[51, 52]. Interestingly, OXPHOS testing in skeletal muscle 
revealed a combined OXPHOS deficiency involving com-
plexes I, II, and IV in one subject [51] and deficiency of the 
OXPHOS complexes I, II, III, and IV in another [52]. A defi-
ciency involving the complexes I, III, and IV was reported 
by Nambot et al. (2017) in two subjects. In another subject, 
only isolated complex IV deficiency was found in cultured 
skin fibroblasts [51]. Authors did not report anemia in the 
affected individuals, but three subjects were found to have 
low serum ferritin [51].
Fe/S‑cluster targeting and further maturation
After [2Fe–2S] clusters are released from the scaffold pro-
tein, they can immediately be incorporated into the apopro-
teins or the OXPHOS complexes I, II, and III. Incorporation 
needs the assistance of chaperone proteins. For further matu-
ration to [4Fe–4S], assistance of a chaperone protein is also 
necessary, i.e., ISCA1 and ISCA2 as well as the folate bind-
ing protein IBA57 [54]. ISCA1 and ISCA2 are important for 
iron incorporation onto the [2Fe–2S]. NFU1 is a dedicated 
chaperone protein for [4Fe–4S] incorporation into com-
plexes I and II as well as for LIAS (lipoic acid synthase), but 
not for mitochondrial aconitase. BOLA3 is another chaper-
one protein that has a similar role as NFU1. IND1 (encoded 
by NUBPL) which stands for the iron–sulfur protein required 
by NADH dehydrogenase, which was initially thought to be 
needed for incorporation of [4Fe–4S] clusters into complex 
I [55]. Its function was, however, reconsidered after studies 
with the A. thaliana ortholog Ind1, which showed that it 
functions as a translation factor necessary for expression of 
multiple complex I subunits [56]. Considering the uncertain 
nature of its action, we included a discussion on the clinical 
features associated with NUBPL dysfunction.
ISCA1
ISCA1 is one of the most recently reported defects in Fe/S-
cluster biogenesis. Together with ISCA2 and IBA57 it acts at 
a late stage of the ISC biosynthesis pathway and is required 
for [4Fe–4S] cluster assembly. In two unrelated families with 
two affected children, ISCA1 deficiency caused by homozy-
gous missense mutations was reported. The affected indi-
viduals had normal prenatal development, but in the young 
infantile period showed developmental delay, poor head 
control and signs of spasticity. Extensive cerebral and cer-
ebellar abnormalities including pachygyria, enlarged lateral 
ventricles and abnormal cerebral and cerebellar white matter 
signals were seen on brain imaging. Seizures were apparent 
within the first months (2nd–5th) of life, and the children 
died between 11 months and 5 years. When documented, 
blood lactate was increased and a lactate peak was seen by 
cerebral MR spectroscopy [57]. Measurements of OXPHOS 
complex activities were not reported.
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ISCA2
Although only 16 subjects with ISCA2 deficiency were 
reported until now, all caused by a missense mutation, an 
apparent uniform phenotype seems to segregate. Affected 
individuals presented a leukodystrophy characterized by dif-
fuse white matter alterations seen on brain MRI extending 
into the corpus callosum and posterior limb of the capsula 
interna, and also alterations in the mesencephalon and cer-
ebellar white matter. In some patients, abnormal cervical 
spinal cord signaling was also seen. The subjects became 
symptomatic after an uneventful pregnancy, between the 
age of three and 7 months. Presenting symptoms were loss 
of fixation with or without nystagmus and loss of acquired 
motor and social skills. Eventually all developed spasticity 
of the upper and lower limbs and optic nerve atrophy. All 
subjects were considered as having a degenerative condition 
and died a few months to 2 years after the onset of the initial 
symptoms [58, 59]. For some subjects, symptoms started 
after an inflammatory episode (infection or vaccine) or after 
mild head trauma [59]. CSF lactate and to a milder extent 
plasma lactate was increased. This was also the case for CSF 
and plasma glycine [59]. Analysis of OXPHOS complex 
activities in subject’s cultured skin fibroblasts revealed that 
complex I was severely impaired but complex II or III were 
normal. In HeLa cells depleted of ISCA2 using siRNA, a 
decreased expression of several ISC bearing proteins (mito-
chondrial aconitase, SDH, NDUFS3, NDUFA9, NDUFB4, 
NDUFA13, UQCRFS1) was found but no decrease of ferro-
chelatase. Activity measurements showed impaired activity 
of the complexes I and II and of mitochondrial aconitase. 
In accordance to its distal action in the ISC biosynthesis 
pathway, no deleterious effect on heme synthesis could be 
detected in ISCA2 depleted cells [58].
IBA57
Since the first publication in 2013 [60], four other papers 
were reported describing subjects with IBA57 deficiency, 
in total now 28 subjects. Three different phenotypes can be 
discerned with IBA57 deficiency, all with involvement of 
the central nervous system. The severity and type of lesions 
and the age of onset of symptoms are variable. Two pheno-
types are associated with early fatal or debilitating outcomes 
[60–63], and one phenotype with a milder phenotype [64]. 
No genotype–phenotype correlations could be made. Most 
of the subjects harbored missense mutations. Insertions with 
frameshifts were also reported [63].
The first described subjects were siblings born from consan-
guineous parents presenting with intra-uterine growth retarda-
tion, polyhydramnion and microcephaly. At birth, they were 
hypotonic and presented with signs of encephalopathy. They 
had dysmorphic features, including retrognathia, high arched 
palate, widely spaced nipples, arthrogryposis of elbows, wrists, 
fingers and knees. Despite prompt adequate intensive support, 
the conditions deteriorated leading to early death. Cerebral 
MRI was abnormal with hypoplasia of the corpus callosum 
and medulla oblongata and bilateral frontoparietal polymicro-
gyria, and severely enlarged lateral ventricles [60].
Subjects with the mildest phenotype presented with spas-
tic paraplegia, variably associated with optic nerve atrophy 
and peripheral neuropathy, abbreviated as SPOAN. Sub-
jects suffered from slowly progressive gait impairment due 
to spastic paraparesis together with peripheral neuropathy 
and superficial sensory loss. Age of onset of gait impair-
ment varied between 3 and 12 years. Central nervous sys-
tem lesions were minor, as all affected subjects led an inde-
pendent adult life, without cognitive impairment. Cerebral 
MRI in one subject showed, aside from bilateral optic nerve 
atrophy, scattered white matter alterations. Only one sub-
ject presented with mild cerebellar and cervical spinal cord 
atrophy [61].
In three reports, a third phenotype was described, all 
together in 15 subjects. The children presented with loss of 
motor and mental skills between 4 and 15 months of age. 
These findings correlated with extensive white matter altera-
tions in cerebrum, cerebellum, mesencephalon and in the 
upper spinal cord. The corpus callosum and basal ganglia 
were not affected [61–63].
Increased lactate in serum and CSF and increased gly-
cine were common biochemical features in most of the 
affected subjects. In all subjects, deficient activity and 
expression of complexes I and II and faulty lipoylation in 
all analysed tissues (lymphoblasts, cultured skin fibro-
blasts and skeletal muscle) were detected [60–63]. None 
of the described subjects had signs of anemia.
Similar as for ISCA2, HeLa cells depleted of IBA57 
using siRNA, showed decreased expression of the ISC 
bearing subunits of complex I, complex II, and complex 
III but not of ferrochelatase.
NFU1
The role of NFU1 in human ISC biogenesis was deduced 
from the biochemical alterations detected in affected sub-
jects. As complexes I and II and lipoylation were defi-
cient, it was presumed that NFU1 acts as a chaperone 
dedicated to ISC incorporation in lipoic acid synthase, 
complex I and complex II. Expression studies demon-
strated ubiquitous expression of the protein, with highest 
expression profiles in brain and heart, which is in paral-
lel with mitochondrial content [65]. Missense [66–68] as 
well as splice site variants [68–70] were reported.
The first reported subjects presented with early onset 
encephalopathy and fatal outcome before the age of 
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1 month [66]. Ten other patients were reported with vari-
able age of onset (between one and 9 months), and fatal 
outcome before the age of 15 months. This permitted a 
classification into three groups. In the first group, the 
affected subjects presented with failure to thrive, pulmo-
nary hypertension, hypotonia and irritability. Cerebral 
MRI showed bilateral extensive white matter alterations. 
Recently, another paper confirmed the severe clinical 
picture in two children aged three and 4 months [71]. In 
a second group the affected individuals presented with 
pulmonary hypertension and regression of acquired skills 
after an intercurrent infection. A third group, with the 
mildest symptoms, showed only pulmonary hypertension 
and variable failure to thrive [70]. Ahting et al. (2015) 
described seven other subjects. All of them had central 
nervous system involvement with evolution into spastic 
tetraparesis and a declining clinical condition. Four of 
them suffered from pulmonary hypertension. One subject 
had dilated cardiomyopathy which became fatal at the age 
of 3 years [68]. Two individuals initially presented with 
early onset decline evolving to a stable spastic tetraparesis 
or paraparesis at adult age [69, 72].
The common feature for all reported subjects was an 
increased serum glycine and defective lipoylation result-
ing in decreased activity of complex II and PDHC (pyru-
vate dehydrogenase complex). Biochemical testing was 
not performed in the two most recently published cases 
[71].
BOLA3
Most reported subjects developed neurological symptoms 
at an early age, including seizures, leading to death before 
the age of 1 year, together with cardiomyopathy. Optic 
nerve atrophy was a variably occurring symptom [41, 66, 
73]. When available, cerebral MRI showed various degrees 
of white matter alterations. Homozygous missense [41, 73] 
and homozygous duplication leading to a frameshift with 
premature a stop codon [66] have been reported.
Only one subject had a milder presentation with slow-
ing of development starting at the age of 6 months. Subse-
quently, a slowly progressive spasticity and ataxia, as well 
as loss of language skills between 3 and 8 years of age were 
observed. Acute regression was seen at the age of 9 years 
with recurrent status epilepticus and worsening of spastic-
ity. This subject finally died at the age of 11 years and was 
found to have only mild cerebral and cerebellar atrophy and 
no white matter changes [41].
Similar to NFU1 deficient subjects, increased lactate 
and glycine are a common feature of subjects with BOLA3 
deficiency, together with defective lipoylation. Similar to 
NFU1 patients, the OXPHOS profile in cultured skin fibro-
blasts and skeletal muscle displayed a decreased activity of 
complexes I and II. When tested, PDHC was also deficient, 
but mitochondrial aconitase was normal [66, 73].
NUBPL
This protein is specifically dedicated to the incorporation 
of [4Fe–4S] clusters into complex I, leading to exclusive 
deficiency of complex I when NUBPL is deficient. Reported 
patients were all heterozygous for exonic missense muta-
tions, deletions or insertions leading to a frameshift and 
premature stop codon. One intronic mutation was found 
to be located at intron 9–10 introducing a cryptic acceptor 
splice site leading to the introduction of an additional 72 bp, 
and finally resulting in a frameshift and nonsense mediated 
decay. This allele was found in heterozygous state with a 
complex genomic rearrangement detected in seven of the 
reported subjects [74–76].
The first reported subjects had isolated encephalopathy 
[74]. Another subject was described with progressive nys-
tagmus, cerebellar ataxia and pyramidal tract signs in adult 
life. Cerebral MRI in the latter showed hyperintense lesions 
in the cerebellum, anterior mesencephalon and pyramidal 
tract [75].
A group of six patients was identified based on their cer-
ebral MRI findings, showing extensive signal abnormalities 
in the cerebellar cortex, deep cerebral white matter and cor-
pus callosum. Interestingly, cerebral white matter and cor-
pus callosum abnormalities improved or even disappeared 
in the course of the disease, while cerebellar abnormalities 
became more extensive and abnormalities in the brainstem 
(basal pons and dorsal medulla oblongata) became visible. 
All subjects presented clinically with slow progression of 
motor function and ataxia, and in the majority of them with 
spasticity. Intellectual capacities varied from normal to 
severely impaired [76].
When reported, lactate was increased in plasma and CSF 
[76]. All described patients showed deficient complex I 
activity.
Conclusion
Considering the strong evolutionary conservation of 
iron–sulfur clusters and its biosynthetic pathway through-
out eukaryotes, it is not surprising that deficiencies in this 
synthesis pathway can cause severe impairment of cellular 
functioning and affect the viability of affected organisms. 
In this review we compiled the acquired knowledge on the 
clinical and genetic features of ISC deficiencies. Strikingly, 
a strict definable ‘ISC biosynthesis deficiency’ phenotype 
cannot be found. Most affected organs are the brain, result-
ing in developmental delay, epilepsy or regression, and 
skeletal muscle involvement leading to muscle weakness. 
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Increased lactate and glycine in body fluids as well as ane-
mia, eventually with the presence of sideroblasts, are possi-
bly accompanying biochemical features associated with ISC 
deficiencies. This clinical and biochemical profile, except for 
increased glycine, is reminiscent of the clinical characteris-
tics reported in the subjects with mitochondriopathies. The 
parallelism is not unexpected as three OXPHOS complexes 
harbor iron–sulfur clusters that function as electron carrier. 
Deficiencies in the cytosolic iron–sulfur cluster synthesis 
pathway have not been reported yet, and will probably result 
in clinical pictures different from those seen in CIA.
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